Current role of antibody therapy in patients with metastatic colorectal cancer.

摘要: In less than 10 years, the number and importance of non-surgical treatment modalities in patients with colorectal cancer (CRC) have increased dramatically, both adjuvant advanced settings. However, despite improvement cytotoxic therapy CRC, many still develop progressive disease unfortunately resistant to 5-fluorouracil/folinic acid, irinotecan oxaliplatin, no effective is known. The rapidly expanding knowledge tumor biology has encouraged optimism for possibility find target tumor-specific mechanisms thereby increase efficacy tolerance. A great 'targeted drugs' are being tested clinical trials some these new drugs, like bevacizumab, cetuximab panitumumab, available routine use health care. These targeted drugs will expand therapeutic arsenal CRC a extent, but they also add complexity CRC. this review, we summarize current status antibody